Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Questions Revlimid Dose, Toxicity And Single-Arm Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncologic Drugs Advisory Committee will be asked whether Celgene’s single-arm study design is adequate to show clinical benefit in a heterogeneous disease like myelodysplastic syndromes.
Advertisement

Related Content

Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
MGI/SuperGen’s Dacogen Is “Approvable” Pending Transfusion Data Analysis
MGI/SuperGen’s Dacogen Is “Approvable” Pending Transfusion Data Analysis

Topics

Advertisement
UsernamePublicRestriction

Register

PS062873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel